Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jeffrey Lafond

Gastroenterology North Chesterfield, VA Medical Doctor

NPI 1780973081 CMS profile 2784513

201 Wadsworth Dr, North Chesterfield, VA 23236

Open in the dashboard

General payments

$11,274

622 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jeffrey Lafond of North Chesterfield, VA is reported in the CMS Open Payments database as having received $11,274 across 622 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,806 90
2024 General $2,280 114
2023 General $2,427 109
2022 General $1,618 101
2021 General $1,501 96
2020 General $682 40
2019 General $960 72

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jeffrey Lafond
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Jeffrey Lafond were reported at $1,806. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Jeffrey Lafond Gastroenterology median Middle half National median
2019 $960 $417 $126–$1,100 $163
2020 $682 $224 $74–$624 $114
2021 $1,501 $352 $106–$1,054 $132
2022 $1,618 $448 $129–$1,270 $149
2023 $2,427 $533 $150–$1,390 $160
2024 $2,280 $605 $160–$1,606 $164
2025 $1,806 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $3,951 198 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $1,649 140 payments
  3. Janssen Biotech, Inc. $1,233 50 payments
  4. QOL Medical, LLC $765 36 payments
  5. Salix Pharmaceuticals, a division of Bausch Health US, LLC $760 44 payments
  6. Genzyme Corporation $588 20 payments
  7. Celgene Corporation $422 31 payments
  8. Pfizer Inc. $415 24 payments
  9. Merck Sharp & Dohme Corporation $213 10 payments
  10. Ardelyx, Inc. $176 11 payments
  11. Other $1,103 58 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,258 621 payments
  2. Consulting Fee $16 1 payment
Products named General payments · program years 2019–2025
  1. RINVOQ $1,661 74 payments
  2. HUMIRA $1,164 59 payments
  3. ENTYVIO $1,044 92 payments
  4. SKYRIZI Immunology $892 45 payments
  5. CREON $671 35 payments
  6. STELARA $629 35 payments
  7. LINZESS $605 34 payments
  8. TREMFYA $603 15 payments
  9. DUPIXENT $588 20 payments
  10. SKYRIZI Immunology $557 24 payments
  11. Other $4,989 291 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

829

Median for Gastroenterology: 569

Drug cost

$323,628

Median for Gastroenterology: $104,976

Branded share of claims

28.6%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Creon Lipase/Protease/Amylase Brand 24 $151,922
Rinvoq Upadacitinib Brand 14 $115,101
Linzess Linaclotide Brand 32 $27,619
Pantoprazole Sodium Generic 153 $7,214
Dexlansoprazole Dr Dexlansoprazole Brand 12 $4,305
Omeprazole Generic 281 $3,948
Clenpiq Sod Picosulf/Mag Ox/Citric Ac Brand 16 $2,714
Sutab Sod Sulf/Pot Chloride/Mag Sulf Brand 13 $2,095
Budesonide Dr Budesonide Brand 14 $1,712
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 25 $1,643

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 42 billing codes

Paid by Medicare

$81,977

Medicare's payments for the services billed

Medicare patients

415

Average age 74

Services billed

724

237 women, 178 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 47%
Diabetes 34%
Ischemic heart disease 33%
Chronic kidney disease 25%
Cancer 21%
Depression 20%
Atrial fibrillation 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 26 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
  • Janssen Biotech, Inc. $437
$437 — —
SKYRIZI
  • AbbVie, Inc. $287
$287 — —
RINVOQ
  • AbbVie, Inc. $266
$266 14 —
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $264
$264 — —
Sucraid
  • QOL Medical, LLC $147
$147 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 26 with Patron

Records

622 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record